Evelo Biosciences’ Atopic Dermatitis Study Fails, Observes Unusually High Placebo Response Rates
Evelo Biosciences Inc (NASDAQ:EVLO) said it observed an unusually high placebo response rate in the first three cohorts of…
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
Chardan Capital Downgrades Evelo Biosciences to Neutral, Announces $2.5 Price Target
Chardan Capital analyst Keay Nakae downgrades Evelo Biosciences (NASDAQ:EVLO) from Buy to Neutral and announces $2.5 price target.
Evelo Biosciences Announces Publication Of Scientific Basis For SINTAX Medicines In Frontiers In Immunology
Peer-reviewed article explains the immunology of the small intestinal axis
Company to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET
CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE)
Evelo Biosciences Filed U.S. Patent Application #20220267716 METHODS AND COMPOSITIONS FOR CULTURING HEMOGLOBIN-DEPENDENT BACTERIA
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=5170&p=104&f=G&l=50&d=PG01&S1=20220825.PD.&OS=PD/20220825&RS=PD/20220825
Chardan Capital Maintains Buy on Evelo Biosciences, Lowers Price Target to $5
Chardan Capital analyst Keay Nakae maintains Evelo Biosciences (NASDAQ:EVLO) with a Buy and lowers the price target from $12 to $5.